STOCK TITAN

Aeglea BioTherapeutics Announces New Presentation Time at Upcoming Investor Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

Aeglea BioTherapeutics (NASDAQ:AGLE) has announced updated details for its Fireside Chat at the Evercore ISI 3rd Annual HealthCONx Conference. The conference is scheduled for December 1-3, 2020, with the Fireside Chat occurring on December 1 at 8:00 a.m. EST. Anthony G. Quinn, M.B. Ch.B., Ph.D., will present. Interested parties can access the live and archived webcast through the Company's website.

Loading...
Loading translation...
Argus Session date unavailable
-0.57% session move Open Argus
Details

News Market Reaction – AGLE

The recorded move for AGLE in the trading session of this news was -0.57%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

AUSTIN, Texas, Nov. 24, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced updated timing for its Fireside Chat presentation at an upcoming investor conference hosted by Evercore.

Updated Conference Details

Conference Name: Evercore ISI 3rd Annual HealthCONx Conference
Conference Date: December 1-3, 2020
Fireside Chat Date/Time: December 1, 2020 at 8:00 a.m. EST
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea's president and chief executive officer

To access the live and archived webcast, visit the Presentations & Events section of the Company's website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. An archived version of the webcasts will also be available through the Company's website for a limited time following the conference.

About Aeglea BioTherapeutics

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. The Company initiated a Phase 1/2 clinical trial of ACN00177 for the treatment of Homocystinuria in the second quarter of 2020. Aeglea has an active discovery platform, with the most advanced program for Cystinuria. For more information, please visit http://aegleabio.com.

(PRNewsfoto/Aeglea BioTherapeutics, Inc.)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/aeglea-biotherapeutics-announces-new-presentation-time-at-upcoming-investor-conference-301180126.html

SOURCE Aeglea BioTherapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the date and time of Aeglea BioTherapeutics' Fireside Chat?

Aeglea BioTherapeutics' Fireside Chat is scheduled for December 1, 2020, at 8:00 a.m. EST.

Where can I watch the Aeglea BioTherapeutics Fireside Chat?

You can watch the Aeglea BioTherapeutics Fireside Chat live and access the archived webcast on the Company's website.

Who will present at the Aeglea BioTherapeutics Fireside Chat?

Anthony G. Quinn, M.B. Ch.B., Ph.D., the president and CEO of Aeglea BioTherapeutics, will present at the Fireside Chat.

What significant designations has Aeglea BioTherapeutics received?

Aeglea BioTherapeutics has received both Rare Pediatric Disease and Breakthrough Therapy Designation for its lead product candidate, pegzilarginase.

Keep reading